ant to standard-dose chemotherapy, these patients often do not receive ABMT. 10 Refractoriness to standard-dose treatment, though, may not necessarily reflect total resistance to To evaluate a strategy of one cycle of dose-intensive chemotherapy for patients with Hodgkin's disease in high-dose therapy, as suggested by occasional successes with dose-intensive therapy in resistant patients. We theresensitive relapse and two cycles for those with refractory disease, 122 patients received dose-intensive fore decided to employ two sequential ABMTs to test in a polar fashion whether dose intensive treatment has a role chemotherapy followed by autotransplant in two consecutive studies. Patients with refractory disease were in the treatment of patients with ostensible resistance to conventional-dose chemotherapy, and to compare their outoffered a second transplant with different conditioning in the absence of progression or excessive toxicity. CR come to that of simultaneously referred patients with sensitive disease, treated with one autotransplant. In patients was present after treatment in 46% while 16% died in the peritransplant period. Of 41 patients with primary with refractory disease, we used two chemotherapeutically dissimilar regimens in order to exploit the theoretical benerefractory disease and 42 with refractory relapse, 24 and 21 respectively received a second cycle. Of these 45 fit of any non-cross resistance between successive treatments. [11][12][13] Two consecutive studies with different conrefractory patients, 12 were in CR and 11 in PR after the first cycle and 10 of these 11 in PR achieved a durditioning regimens were performed, while maintaining the general study design. able CR with the second transplant. The CR rate is 37% in patients with refractory relapse and 19% in those with primary refractory disease. At a median follow-up of 4 years, median survival is 45 months. Progressionfree survival of the refractory patients who could
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Patients and methods receive a second cycle was similar to that of patients with sensitive disease. A sequential transplant strategy is feasible. A subgroup of patients with refractory disPatient selection ease can achieve long-term survival after sequential BMT. Keywords: Hodgkin's disease; double transplant; doseAll consecutive patients referred with histologically documented Hodgkin's disease that had not responded to or had intensive therapy; refractory disease relapsed after conventional-dose chemotherapy were eligible for dose-intensive treatment with autotransplantation according to protocols approved by the institutional review Dose-intensive chemotherapy with autologous bone marboard of New York Medical College. All patients signed row transplantation (ABMT) is considered appropriate an approved, informed consent. Patients with disease resisttreatment for patients with relapsing Hodgkin's disease. [1] [2] [3] [4] [5] [6] [7] [8] ant to initial or subsequent conventional chemotherapy Relapsing disease, however, is prognostically different were eligible to receive a second cycle of dose-intensive from partially responsive, non-responsive and progressive therapy, provided they had not progressed after the first disease. 9 While all are usually classified under the broad transplant and had recovered sufficiently with respect to rubric of refractory illness, relapsing patients are thought physiologic functions. to have response and survival characteristics superior to Patients were classified as having sensitive relapse, that of the other categories, all of which are considered to refractory relapse, or primary refractory disease. 10 Sensitive be chemoresistant and truly refractory disease. Because of relapse was defined as a complete or partial response to the perceived poor outcome of patients with disease resistconventional salvage chemotherapy prior to entry into the protocol; refractory relapse denoted absence of response to standard intensity salvage therapy despite previous prior to conditioning treatment. Standard criteria for commercially for the first study. Non-mobilized peripheral response evaluation were used. 16 However, radiographic blood progenitor cells (PSC) were given if a sufficient abnormalities persistent and stable beyond 6 months in quantity of marrow could not be collected or in case of patients who had no other clinical evidence of disease were marrow involvement. All marrow and peripheral stem cells characterized as complete remission. Survival was calcuwere collected as described elsewhere 14 prior to the first lated from the first day of chemotherapy conditioning to conditioning.
the last day of follow-up.
Study II: From September 1990 to December 1993, patients were initially treated with TMJ as described above. Data evaluation Those with refractory disease were given a second conData management was performed on commercially availditioning regimen of cyclophosphamide, 5-7.5 g/m 2 and able, customized data base and spreadsheet programs and etoposide, 1800-2400 mg/m 2 (EC). Total body irradiation statistical calculations with the BMDP statistical package (TBI), 1000 cGy, was additionally administered in the and other programs designed ad hoc. 17 Categorical data absence of prior radiotherapy to the spinal cord and of marwere compared by the 2 test and, where indicated, Fisher's row involvement. Hematopoietic growth factors were used exact test. Continuous parameters were compared by twofor the collection of PSC and also to augment post-transgroup or paired Student's t-test after correction and testing plant recovery.
for distribution and comparability of the variance, or Mann-Whitney's or Wilcoxon's non-parametric tests, as Ancillary treatment: All blood products were irradiated appropriate. 17, 18 Survival curves were calculated with prior to infusion. Patients who were seronegative for antiKaplan-Meier's product-limit method for overall survival and a life table method for progression-free survival; a log- Initial characteristics of the 122 patients are listed in Table  2 . Sixty-nine patients with recurrent/relapsed disease were 
Previous irradiation Of the 39 patients with sensitive relapse, 13 had no radio-53 40% 20% 28% 9%
graphic or clinical evidence of disease following salvage therapy, and 26 had responsive relapsed disease with residual radiographic abnormalities. Of 83 patients with disease refractory to chemotherapy, 41 had responded to evaluation while one progressed in the peritransplant period. Of the 26 patients entering the study with residual initial chemotherapy but not to salvage (refractory relapse), and 42 had persistent or progressive disease after initial disease, 21 (81%, with 95% confidence interval 60-93%) achieved complete remission (CR), three had partial induction therapy (primary refractory). There were more patients with primary refractory disease in the first study.
response (PR), one had progressive disease (PD) and one died in the peritransplant period. Ten of the 13 patients The number of patients who received the various conditioning regimens is shown in Table 3 . The 20 patients who, after entering the study with no evidence of disease, have been observed for 18 months or longer are still in with sensitive relapse in the first study received one treatment with BEC-2 and 19 patients with sensitive relapse in remission. The 18-month progression-free proportion among those of the responding patients with sensitive the second study had TMJ. Of 79 patients with refractory disease who completed the first transplant, 34 received only relapse who had residual disease at entry is 15/23 (65%). Median time to tumor progression, counting from day of one conditioning. Of these 34 patients, nine died in the peritransplant period, 10 progressed after the first ABMT, and transplant, was 18 months (range, 3-78) in the 35 patients with sensitive relapse who had CR or PR at the end of treat-15 patients were not offered the initially planned second ABMT on account of excessive toxicity during the first ment. cycle. Forty-five patients went on to receive the second conditioning.
Refractory disease: Of the 83 patients with refractory disease, 16 died in the peritransplant period, 23 (28%, with 95% confidence limits 18-38%) achieved CR and 15 PR.
Response and response duration
Progressive disease was noted in 23 patients. The difference in response rates between patients with sensitive and refracSensitive disease: Tumor response is indicated in Table 4 . Of the 39 patients with sensitive relapse, 13 had entered the tory disease was significant. Of the 38 patients with refractory disease who achieved either PR or CR, all of whom study with no evidence of disease. Twelve of these patients maintained their disease-free status at the end-of-treatment have been observed 18 months or longer, 23 patients (61%) are in continuing remission with a median progression-free survival of 15 months. Eleven patients with refractory disease received a second ABMT after achieving a less than complete response with the first cycle, and five of these patients had radiographic resolution of disease after the second treatment, while the other five remained long-term progression-free. These 10 patients are alive without relapse, 8 months to 7 years (median, 29 months) after entry into the study and one, who was given BEC-2 followed by TMJ, died 16 months into the study of Pneumocystis carinii pneumonia contracted while under treatment with steroids for pulmonary fibrosis.
Survival
The median follow-up of study patients is now 4 years, with a range of 4-87 months. Four patients were lost to follow-up 4-26 months after the start of treatment. The actuarial survival probability according to prior response status is shown in Figure 1 .
When the survival and progression-free survival of patients with sensitive relapse was compared to that of patients with refractory relapse or primary refractory disease, irrespective of the number of cycles administered, it was apparent that patients with sensitive relapse had a superior survival (P = 0.007). Patients with sensitive relapse receiving one transplant had a superior survival to those with refractory disease given two transplants, who in turn had a survival significantly superior to that of patients with refractory disease receiving one transplant only. Progression-free survival of patients with refractory disease receiving two cycles of dose-intensive therapy, compared to that of patients with sensitive relapse, was not different. This finding was clearly distinct from those patients with probability for patients with sensitive relapse and those with refractory disease who could receive both transplants is plotted in Figure 2 .
Other characteristics that influenced survival were the initial disease stage and prior radiation therapy, while no significant differences were found when comparing the survival curves according to age, gender, number of treatment regimens prior to ABMT, and autotransplant treatment protocol. The survival curves of patients with sensitive relapse, regardless of whether there were initial radiographic abnormalities or not, were superimposable.
Toxicity
The major toxicities observed are outlined in Table 5 . Two patients in each of the two studies were not evaluable for toxicity. One of the four patients who had evidence of myelodysplastic syndrome developed acute leukemia, two others were treated with allogeneic BMT, and one of them survives to date. Serious or lethal hepatitis and interstitial pneumonitis were more frequent in patients treated with the BEC-2 regimen. In addition to the eight patients developing opportunistic pulmonary infections supervening in the face 453 Table 5 Severe toxicity
for maximum doses of agents with dissimilar extramedullary toxicity. and survival superior to that of patients with refractory disease. However, patients undergoing two cycles of doseintensive therapy for refractory disease had a progressionfree survival comparable to that seen in patients with sensitive disease. of steroid therapy that was necessary to treat carmustineThis interesting phenomenon could represent a culling induced pneumonitis. Interstitial pneumonia was present in process whereby patients selected for a second ABMT have three cases of early death in the second study. a better prognosis than refractory patients in general, or it Prohibitive neurologic toxicity, severe myalgias requirmay represent a genuine alteration in the biology of the ing morphine, four cases of ileus/acute abdomen requiring disease by the second autotransplant itself. With regard to surgery and four more with confusion, lethargy and cerebelthe latter possibility, a relevant observation is that of the lar signs in patients receiving a second cycle of dose-intenpartial responders at the end of the first ABMT, half of sive therapy with TAVE led to the adoption of TMJ as the whom were converted into complete responders, and all of conditioning regimen for the second transplant. Neurologic whom, except in one case of fatal pulmonary toxicity, are toxicity was not seen with TMJ given as either the second alive without relapse 8 months to 7 years after treatment. or initial therapy.
Whether a delayed complete response would have been Except for the initial treatment of patients receiving observed, had a second cycle not been given, is unclear. BEC-2, and neurotoxicity in patients receiving TAVE as a
The fact is that such delay was not observed in responding second conditioning, there was no difference in the type patients who received a single ABMT. and severity of recorded toxicity between the first and the Radiographic abnormalities persisted in some patients second autotransplants.
who had no clinical evidence of progression or active disThe average length of hospital stay for the first ABMT ease. Unchanged radiographic abnormalities are not always was 34 days (s.d. 19 days) for the first study and 25 (s.d.
indicative of active disease and must be correlated with the 12) for the second; a difference cannot be detected with clinical status of the patient. 25 We subjected several of these sufficient power. There was no difference between the durpatients to biopsy and frequently found only fibrous tissue. ation of hospital stay for the first and the second course of ABMT.
Patients with refractory relapse of Hodgkin's disease or primary refractory disease are often not offered dose-intensive therapy. A subset of our refractory patients, in fact, Discussion achieved durable complete remissions with dose-intensive chemotherapy. This subgroup comprises patients who achiTherapy for disseminated Hodgkin's disease represents a eve stabilization or response after the first transplant. Transtriumph of chemotherapy over a malignancy otherwise fatal plantation can thus identify those patients with disease in at least half of patients. 21 However, 15-20% of patients refractory to standard chemotherapy who are likely to benedo not respond to therapy and 22-25% relapse.
22, 23 For fit from a second cycle. When such patients underwent a patients who relapse following conventional chemotherapy, second transplant in our program, their progression-free some success can be achieved with either an identical or survival was similar to that of patients with disease responalternative chemotherapy, depending on the duration of the sive to standard chemotherapy, a group that is traditionally prior complete remission. 9, 22, 24 considered to be likely to benefit from transplantation. In patients with disease responsive to conventional sal-A comparison of our results with those of other authors, vage chemotherapy, consolidation with dose-intensive therhowever, would be invalid because the term 'refractory apy and autologous transplantation is now being employed, disease', in various studies, is limited to those patients particularly for those patients relapsing in less than a year. who experienced progression of disease while receiving In patients with disease refractory at the outset or at relapse, standard-dose treatment. probability of success with dose-intensive therapy has been
The question, whether double dose-intensive chemodeemed to be low. Such patients are often not even contherapy with autotransplant selects patients with a better sidered for dose-intensive therapy. We offered patients with prognosis or alters the course of the disease, should be refractory or relapsed disease two consecutive, noncrossaddressed by future controlled studies. resistant chemotherapy combinations. This strategy allows
